Tyra Biosciences reports FY 2023 net loss $69.1M; $403.5M cash after $200M PIPE

Tyra Biosciences, Inc.

Q4 2023 net loss $22.8M vs $12.9M; FY net loss $69.1M vs $55.3M.
Closed $200M PIPE in Feb 2024; pro-forma cash $403.5M to fund operations through at least 2026.
TYRA-300 Phase 1 SURF301 initial data expected 2H 2024; Phase 2 IND for achondroplasia on track for 2H 2024.
FDA granted Rare Pediatric Disease Designation for TYRA-300 in achondroplasia (Jan 2024).
Initiated SURF201 Phase 1 study for TYRA-200 in FGFR2-altered cholangiocarcinoma.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tyra Biosciences, Inc. reported the fiscal year ended December 31, 2023 results: net income Full year 2023 net loss was $69.1 million.

Period: the fiscal year ended December 31, 2023
Net income: Full year 2023 net loss was $69.1 million
Result: reported results

Exact text from the filing

Full year 2023 net loss was $69.1 million compared to $55.3 million for the same period in 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tyra Biosciences, Inc. reported the fourth quarter and full year ended December 31, 2023 results: net income net loss was $22.8 million.

Period: the fourth quarter and full year ended December 31, 2023
Net income: net loss was $22.8 million
Result: reported results

Exact text from the filing

Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter and fiscal year ended December 31, 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tyra Biosciences, Inc. reported the fourth quarter ended December 31, 2023 results: net income Fourth quarter 2023 net loss was $22.8 million.

Period: the fourth quarter ended December 31, 2023
Net income: Fourth quarter 2023 net loss was $22.8 million
Result: reported results

Exact text from the filing

Fourth quarter 2023 net loss was $22.8 million compared to $12.9 million for the same period in 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-033455

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.